+

WO2001043779A3 - Anti-hiv-1 conjugates for treatment of hiv disease - Google Patents

Anti-hiv-1 conjugates for treatment of hiv disease Download PDF

Info

Publication number
WO2001043779A3
WO2001043779A3 PCT/US2000/034032 US0034032W WO0143779A3 WO 2001043779 A3 WO2001043779 A3 WO 2001043779A3 US 0034032 W US0034032 W US 0034032W WO 0143779 A3 WO0143779 A3 WO 0143779A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
molecule
conjugate
conjugates
provides
Prior art date
Application number
PCT/US2000/034032
Other languages
French (fr)
Other versions
WO2001043779A2 (en
Inventor
Michael Fung
David Thomas
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Priority to AU22657/01A priority Critical patent/AU2265701A/en
Publication of WO2001043779A2 publication Critical patent/WO2001043779A2/en
Publication of WO2001043779A3 publication Critical patent/WO2001043779A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a conjugate of an anti-CD4 molecule and an antichemokine receptor molecule. These molecules may be antibodies. The anti-CD4 molecule may be an antibody that inhibits HIV-1 infection of CD4+ cells and also inhibits syncytia formation between CD4+ cells, but does not cause immunosuppression in humans. The anti-chemokine receptor antibody may be an anti-CCR5 molecule. The invention also provides for conjugate of an anti-CD4 molecule and an HIV-1 fusion inhibiting peptide. Both types of conjugates may be formed by chemical methods and may or may not include a linker. Numerous types of linkers may be used. Both types of conjugates may also be expressed as recombinant proteins with or without linkers. The invention also provides a method of treating HIV-1 disease by providing a conjugate to a subject. The conjugate may be provided by providing the subject with a recombinant nucleic acid in a viral vector.
PCT/US2000/034032 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease WO2001043779A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22657/01A AU2265701A (en) 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17118799P 1999-12-16 1999-12-16
US60/171,187 1999-12-16

Publications (2)

Publication Number Publication Date
WO2001043779A2 WO2001043779A2 (en) 2001-06-21
WO2001043779A3 true WO2001043779A3 (en) 2002-05-10

Family

ID=22622858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034032 WO2001043779A2 (en) 1999-12-16 2000-12-15 Anti-hiv-1 conjugates for treatment of hiv disease

Country Status (2)

Country Link
AU (1) AU2265701A (en)
WO (1) WO2001043779A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471136A1 (en) * 2001-12-21 2003-07-03 Micromet Ag Mono-and dual chemokine/cytokine constructs
KR20070050934A (en) * 2004-08-30 2007-05-16 바이엘 쉐링 파마 악티엔게젤샤프트 Method of treating HIV infection by T-cell regulation
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) * 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
CN101516914A (en) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 Antibodies against CCR5 and uses thereof
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
WO2010028797A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028795A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
ES2574988T3 (en) * 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Peptides derived from HIV-1 integrase stimulants that interfere with the Rev-integrase protein
RU2517084C2 (en) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Method and means for inhibiting production or enhancing protein p24 elimination
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20160102137A1 (en) * 2014-09-30 2016-04-14 California Institute Of Technology Crosslinked anti-hiv-1 compositions for potent and broad neutralization
WO2016149695A1 (en) * 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
MX2017013687A (en) * 2015-04-24 2018-07-06 Viiv Healthcare Uk No 5 Ltd Polypeptides targeting hiv fusion.
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
EP4351647A1 (en) * 2021-06-10 2024-04-17 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Antibody-cd4 conjugates and methods of using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
WO1998015569A1 (en) * 1996-10-09 1998-04-16 Dana-Farber Cancer Institute Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
US5871732A (en) * 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
WO1999036091A2 (en) * 1998-01-15 1999-07-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Method for inhibiting cd95-independent apoptosis in aids
WO2000035409A2 (en) * 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Hiv-i fusion inhibition compounds
WO2001070262A2 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871732A (en) * 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
WO1998015569A1 (en) * 1996-10-09 1998-04-16 Dana-Farber Cancer Institute Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
WO1999036091A2 (en) * 1998-01-15 1999-07-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Method for inhibiting cd95-independent apoptosis in aids
WO2000035409A2 (en) * 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Hiv-i fusion inhibition compounds
WO2001070262A2 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ZHANG, HUIZHONG ET AL: "Blocking HIV-1 infection in SupT1 and peripheral blood mononuclear cells by anti-CD4 and anti-CXCR4 antibodies", XP002184173, retrieved from STN Database accession no. 132:346398 *
HOXIE, JAMES A. (1) ET AL: "CD4 -independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2.", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, (DEC., 1998) VOL. 41, NO. 1-2, PP. 197-211., XP001041655 *
XIBAO YU FENZI MIANYIXUE ZAZHI (1999), 15(4), 278-280 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Also Published As

Publication number Publication date
AU2265701A (en) 2001-06-25
WO2001043779A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
WO2001043779A3 (en) Anti-hiv-1 conjugates for treatment of hiv disease
Pollard et al. Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region.
US7101552B2 (en) Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
AT398080B (en) IMMORTALIZED CELL LINE, METHOD FOR THEIR PRODUCTION AND METHOD FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES, AND DIAGNOSTIC METHODS AND MEANS
CA2102511A1 (en) Heteroconjugate antibodies for treatment of hiv infection
WO2003033666A3 (en) Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US20060204986A1 (en) Immunogen
CA2450476A1 (en) A soluble complex comprising a retroviral surface glycoprotein
JP2019524687A5 (en)
CA2298934A1 (en) Vectors derived from antibodies for transferring substances into cells
Leaman et al. Immunogenic display of purified chemically cross-linked HIV-1 spikes
Sattentau et al. Antibody neutralization of HIV-1 and the potential for vaccine design
Pardridge et al. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody
Song et al. Distinct HIV-1 neutralization potency profiles of ibalizumab-based bispecific antibodies
CN103328001B (en) Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
RU2562165C2 (en) Alphabodies for hiv penetration inhibition
WO1991009625A1 (en) Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
JP2002538814A5 (en)
Du et al. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
CA2073060A1 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
Gavrilyuk et al. Potent inhibition of HIV-1 entry with a chemically programmed antibody aided by an efficient organocatalytic synthesis
Dorgham et al. Reverse Immunology Approach to Define a New HIV‐gp41‐Neutralizing Epitope
Wang et al. Synthetic AIDS vaccine by targeting HIV receptor
DE69008701T2 (en) A COMPOSITION CONTAINING A B-EPITOP OF THE ENVELOPE GLYCOPROTEIN OF A RETROVIRUS AND A T-EPITOP OF ANOTHER PROTEIN OF THIS RETROVIRUS.
Chen et al. HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载